Fuzapladib (sodium) - HY-19151A
Nur noch %1 verfügbar
Catalog #
HY-19151A
Ab
227,00 €
Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site[1][2].
| Datasheet URL | http://file.medchemexpress.com/batch_PDF/HY-19151A/Fuzapladib-sodium-DataSheet-MedChemExpress.pdf |
|---|---|
| Shipping | Room Temperature |
| Application | COVID-19-immunoregulation |
| Alternative Names | IS-741 (sodium) |
| CAS | 141284-73-3 |
| Storage | -20°C, 3 years; 4°C, 2 years (Powder) |
| MWT | 402.39 |
| Solubility | DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C) |
| Clinical Information | No Development Reported |
| Target | Integrin;Phospholipase |
| Application: | COVID-19-immunoregulation |
|---|